Celgene
Global biopharmaceutical company committed to improving the lives of patients worldwide.
Employees
Share price
$108.24
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | $74.0b | Acquisition | |
| Total Funding | 000k | ||
Vedanta Capital(exited)
Rho Ventures(exited)
InterWest Partners(exited)
ARCH Venture Partners(exited)
NeoMed(exited)
Apple Tree Partners(exited)
Edelson Technology Ventures(exited)
Asseily Ventures(exited)
CHL Medical Partners(exited)
| EUR | 2015 | 2016 | 2017 | 2018 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | 18 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | 46 % | 40 % |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | 23 % | 26 % |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 28 % | 29 % |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
ACQUISITION by Eli Lilly May 2018
exited
ACQUISITION by Adaptive Biotechnologies Jan 2015
ACQUISITION by Celgene Jan 2018
exited
exited
exited
ACQUISITION by Ipsen Jun 2022
ACQUISITION by Celgene Dec 2009